ストックスクリーナーアプリを入手
1.65
3.51%
-0.06
アフターアワーズ：
1.73
0.08
+4.85%
前日終値:
$1.71
開ける：
$1.71
24時間の取引高:
98,911
Relative Volume:
0.43
時価総額：
$26.59M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-24.31%
1か月 パフォーマンス:
-27.31%
6か月 パフォーマンス:
-96.30%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$1.5667
$1.71
1週間の範囲:
$1.5667
$2.1922
52週間の値動き範囲:
$1.5667
$53.79
Q 32 Bio Inc Stock (QTTB) Company Profile
QTTB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
QTTB
Q 32 Bio Inc
|
1.65 | 26.59M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Q 32 Bio Inc Stock (QTTB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-11 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2025-02-11 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2024-12-11 | ダウングレード | Guggenheim | Buy → Neutral |
| 2024-12-11 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-12-11 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2024-12-11 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-12-06 | 開始されました | BMO Capital Markets | Outperform |
| 2024-10-24 | 開始されました | Raymond James | Strong Buy |
| 2024-09-11 | 開始されました | Wells Fargo | Overweight |
| 2024-06-17 | 開始されました | Guggenheim | Buy |
| 2024-05-21 | 開始されました | Leerink Partners | Outperform |
| 2024-04-11 | 開始されました | Oppenheimer | Outperform |
| 2024-04-02 | 開始されました | Piper Sandler | Overweight |
| 2023-07-28 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2022-02-22 | 繰り返されました | BTIG Research | Neutral |
| 2022-02-22 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2022-02-22 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-03-02 | 開始されました | Stifel | Hold |
| 2020-12-14 | 再開されました | H.C. Wainwright | Buy |
| 2020-08-11 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-06-25 | 再開されました | BofA/Merrill | Buy |
| 2020-05-13 | 開始されました | RBC Capital Mkts | Outperform |
| 2020-03-16 | アップグレード | Oppenheimer | Perform → Outperform |
| 2020-02-24 | 開始されました | Chardan Capital Markets | Buy |
| 2019-11-01 | 開始されました | Oppenheimer | Perform |
| 2019-09-10 | 開始されました | Robert W. Baird | Outperform |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
すべてを表示
Q 32 Bio Inc (QTTB) 最新ニュース
Layoff Tracker: Arbutus Cuts 57% of Workforce - BioSpace
QTTB stock touches 52-week low at $1.79 amid market challenges - Investing.com India
Fierce Biotech Layoff Tracker 2025: Elevation eliminates 70% of staff; Vaxart trims team - Fierce Biotech
Oppenheimer maintains Q32 Bio at Outperform, $20 target - Investing.com
Oppenheimer maintains Q32 Bio at Outperform, $20 target By Investing.com - Investing.com UK
Wells Fargo & Company Lowers Q32 Bio (NASDAQ:QTTB) Price Target to $15.00 - Defense World
Q32 Bio price target lowered to $15 from $16 at Wells Fargo - TipRanks
Q32 Bio Inc’s Intellectual Property Challenges: Navigating Risks and Competitive Pressures - TipRanks
Q32 Bio Reports Promising Trial Results and Financials - TipRanks
Q32 Bio: Q4 Earnings Snapshot - Midland Daily News
Q32 Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Q32 Bio Inc. SEC 10-K Report - TradingView
Q32 Bio: Q4 Earnings Snapshot -March 11, 2025 at 07:21 am EDT - Marketscreener.com
Q32 Bio's Breakthrough: Alopecia Drug Success Backed by $78M War Chest - StockTitan
Q32 Bio Inc. (NASDAQ:QTTB) Shares Purchased by Rhumbline Advisers - Defense World
Q32 Bio presents results from SIGNAL-AA Part 2a trial of bempikibart - TipRanks
Q32 Bio (QTTB) Projected to Post Earnings on Tuesday - Defense World
Can This New Alopecia Drug Maintain Hair Growth After Treatment Stops? Q32 Bio's Trial Reveals Surprising Results - StockTitan
Q32 Bio Inc. (NASDAQ:QTTB) Receives $24.86 Average PT from Brokerages - Defense World
Q32 Bio Inc expected to post a loss of $1.51 a shareEarnings Preview - TradingView
Reviewing Q32 Bio (NASDAQ:QTTB) & Ardelyx (NASDAQ:ARDX) - Defense World
Finance Watch: BridgeBio’s Oncology Spinout Reveals Go-Public Plan - Citeline News & Insights
Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting - Longview News-Journal
Can This New Antibody Treatment Finally Solve Severe Alopecia Areata? AAD Meeting Will Reveal Key Data - Stock Titan
QTTB stock touches 52-week low at $2.27 amid market challenges - Investing.com Australia
QTTB stock touches 52-week low at $2.27 amid market challenges By Investing.com - Investing.com South Africa
Q32 Bio to Participate in Upcoming March Investor Conferences - PR Newswire
How Q32 Bio Plans to Showcase Its Immune Therapeutics Pipeline to Investors This March - Stock Titan
IPOs Numbers Rise In 2024 But Dwindling Returns Could Diminish Potential In 2025 - Citeline News & Insights
Savant Capital LLC Makes New $53,000 Investment in Q32 Bio Inc. (NASDAQ:QTTB) - Defense World
QTTB stock touches 52-week low at $2.44 amid market challenges - Investing.com India
Piper Sandler cuts Q32 Bio stock rating to neutral, slashes target - MSN
What is Leerink Partnrs’ Forecast for Q32 Bio Q1 Earnings? - Defense World
Petri Dish: a new AbbVie deal, layoffs, and CFO departures - The Business Journals
Bleakley Financial Group LLC Invests $149,000 in Q32 Bio Inc. (NASDAQ:QTTB) - Defense World
Q32 Bio refocuses on alopecia treatment, ends renal trial - MSN
BMO cuts Q32 Bio stock rating, slashes price target to $3 - MSN
BMO Capital Downgrades Q32 Bio (LSE:0T6G) - Nasdaq
Q32 Bio (NASDAQ:QTTB) Lowered to “Market Perform” Rating by BMO Capital Markets - Defense World
Finance Watch: Third Harmonic, Q32 Bio Cut Jobs To Focus On Lead Assets - insights.citeline.com
Q 32 Bio Inc (QTTB) 財務データ
Q 32 Bio Inc (QTTB) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
1.05%
1.79%
大文字化:
|
ボリューム (24 時間):